(VIANEWS) – Eli Lilly and Company (LLY), Genmab (GMAB), Great Elm Capital Corp. (GECC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Eli Lilly and Company (LLY)
19.2% sales growth and 48.44% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.8.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 135.11. Meaning, the purchaser of the share is investing $135.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 48.44%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Eli Lilly and Company’s EBITDA is 22.43.
Yearly Top and Bottom Value
Eli Lilly and Company’s stock is valued at $783.62 at 15:22 EST, below its 52-week high of $794.47 and way higher than its 52-week low of $309.32.
2. Genmab (GMAB)
17.6% sales growth and 14.78% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.96.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 30.6. Meaning, the purchaser of the share is investing $30.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.78%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 4400% and 1136.7%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Genmab’s EBITDA is 0.92.
Moving Average
Genmab’s worth is below its 50-day moving average of $29.47 and way below its 200-day moving average of $34.30.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.9%, now sitting on 16.47B for the twelve trailing months.
3. Great Elm Capital Corp. (GECC)
9.4% sales growth and 14.3% return on equity
Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments. The fund prefers to invest in media, commercial services and supplies, healthcare, telecommunication services, communications equipment. It typically makes equity investments between $3 million and $10 million in companies with revenues between $3 million and $75 million.
Earnings Per Share
As for profitability, Great Elm Capital Corp. has a trailing twelve months EPS of $1.71.
PE Ratio
Great Elm Capital Corp. has a trailing twelve months price to earnings ratio of 6.28. Meaning, the purchaser of the share is investing $6.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.3%.
Moving Average
Great Elm Capital Corp.’s worth is below its 50-day moving average of $10.76 and way above its 200-day moving average of $9.41.
Yearly Top and Bottom Value
Great Elm Capital Corp.’s stock is valued at $10.74 at 15:22 EST, below its 52-week high of $11.82 and way above its 52-week low of $7.51.
4. CrossFirst Bankshares (CFB)
7% sales growth and 10.13% return on equity
CrossFirst Bankshares, Inc. operates as the bank holding company for CrossFirst Bank that provides various banking and financial services to businesses, business owners, professionals, and its personal networks. The company offers commercial real estate, construction and land development, 1-4 family real estate, multifamily real estate, commercial and industrial, energy, and consumer loans. It also provides a range of deposit products consisting of non-interest-bearing demand and interest-bearing deposits, which include transaction accounts, savings accounts, money market accounts, and certificates of deposit; and personal and business checking and savings accounts, as well as negotiable order of withdrawal accounts; and brokered and reciprocal deposits. In addition, the company offers international banking services; treasury management services; automated teller machine access; and mobile banking services. Further, it holds investments in marketable securities. It has full-service banking offices in Kansas, Missouri, Oklahoma, Arizona, Colorado, New Mexico, and Texas. CrossFirst Bankshares, Inc. was founded in 2007 and is headquartered in Leawood, Kansas.
Earnings Per Share
As for profitability, CrossFirst Bankshares has a trailing twelve months EPS of $1.34.
PE Ratio
CrossFirst Bankshares has a trailing twelve months price to earnings ratio of 9.83. Meaning, the purchaser of the share is investing $9.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.13%.
Moving Average
CrossFirst Bankshares’s worth is below its 50-day moving average of $13.44 and way higher than its 200-day moving average of $11.45.
Sales Growth
CrossFirst Bankshares’s sales growth is 3.5% for the ongoing quarter and 7% for the next.
Yearly Top and Bottom Value
CrossFirst Bankshares’s stock is valued at $13.17 at 15:22 EST, way below its 52-week high of $15.07 and way above its 52-week low of $9.29.
